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Abstract
Background—Programs to prevent mother-to-child HIV transmission (PMTCT) are plagued by 
loss to follow-up (LTFU) of HIV-exposed infants. We assessed if providing combination 
antiretroviral therapy (cART) to HIV-infected mothers was associated with reduced LTFU of their 
HIV-exposed infants in Kinshasa, DR Congo.
Methods—We constructed a cohort of mother-infant pairs using routinely collected clinical data. 
Maternal cART eligibility was based on national guidelines in effect at the time. Infants were 
considered LTFU following three failed tracking attempts after a missed visit or if more than six 
months passed since they were last seen in clinic. Statistical methods accounted for competing 
risks (e.g. death).
Results—1318 infants enrolled at a median age of 2.6 weeks (interquartile range [IQR]: 2.1-6.9), 
at which point 24% of mothers were receiving cART. Overall, 5% of infants never returned to 
care following enrollment and 18% were LTFU by 18 months. The 18-month cumulative 
incidence of LTFU was 8% among infants whose mothers initiated cART by infant enrollment 
and 20% among infants whose mothers were not yet on cART. Adjusted for baseline factors, 
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infants whose mothers were not on cART were over twice as likely to be LTFU, with a 
subdistribution hazard ratio of 2.75 (95% confidence limit: 1.81, 4.16). The association remained 
strong regardless of maternal CD4 count at infant enrollment.
Conclusion—Increasing access to cART for pregnant women could improve retention of HIV-
exposed infants, thereby increasing the clinical and population-level impacts of PMTCT 
interventions and access to early cART for HIV-infected infants.
Keywords
HIV-exposed infants; Prevention of mother-to-child HIV transmission (PMTCT); Pediatric HIV; 
Loss to follow-up; Retention in care; Democratic Republic of Congo
INTRODUCTION
Despite the scale-up of prevention of mother-to-child HIV transmission (PMTCT) programs 
worldwide, an estimated 260,000 children continue to be infected with HIV each year. 1 The 
ongoing pediatric HIV epidemic and associated mortality is driven in part by the 
overwhelming number of HIV-exposed infants who are lost to follow-up (LTFU) from 
PMTCT care. A recent meta-analysis of 11 studies conducted in sub-Saharan Africa 
estimated that 34% of HIV-exposed infants are lost from care by three months of age, with 
some settings reporting over 70% LTFU. 2 Available antiretroviral regimens can greatly 
reduce vertical HIV transmission, 3 but only a marginal impact on population-level 
transmission will be achieved if program retention remains low. 4
At the clinical level, ensuring HIV-exposed infants are retained in care is necessary to 
administer HIV tests, provide prophylactic regimens, monitor breastfeeding, and provide 
other services such as vaccinations. LTFU of HIV-exposed infants also impedes early 
initiation of combination antiretroviral therapy (cART) for HIV-infected infants. Early 
cART initiation is critical because, without treatment, a third of infants will die within the 
first year of life and half within two years. 5,6
Despite the importance of retaining HIV-exposed infants in care, few modifiable risk factors 
for infant LTFU are known. Evidence suggests that HIV-infected adults who receive cART 
are less likely to be LTFU than those who do not receive cART. 7 As HIV-exposed infants 
depend on their caregivers to bring them to care, we hypothesized that provision of cART to 
HIV-infected caregivers may also play a role in the retention of their infants. The goal of 
this study was to assess if providing cART to HIV-infected mothers was associated with 
reduced LTFU of HIV-exposed infants in a large HIV program in Kinshasa, Democratic 
Republic of Congo (DRC) where the prevalence of HIV among women seeking antenatal 
care is estimated to be 2%. 8
METHODS
Study population
We used data from HIV-exposed infants who received care between January 1, 2007 and 
July 31, 2013 in a family-centered HIV program implemented at two centralized sites in 
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Kinshasa with technical assistance provided by the University of North Carolina at Chapel 
Hill (UNC-DRC program). The study clinics, which were integrated into the existing 
healthcare system in Kinshasa and supervised by the government, provided comprehensive 
care (including routine PMTCT services) to individuals identified through a large referral 
network that included 90 antenatal care facilities and 32 TB clinics. Enrollees were 
classified as ‘exposed infants’ if they were <18 months of age at the time of enrollment and 
did not yet have a confirmed HIV-positive diagnosis. HIV exposure was confirmed by a 
positive HIV antibody test in the mother or in the infant at <18 months of age.
We linked routinely collected data from HIV-exposed infants with data from their mothers 
to construct a cohort of mother-infant pairs. So that all infants could experience the entire 
18-month follow-up period, we only included infants who were enrolled before January 1, 
2012. Infants enrolled after 18 months of age and those who could not be matched to a 
mother receiving care in the UNC-DRC program by the time of infant enrollment were 
excluded. Since duration of maternal enrollment in care may be an important confounder 
and modifier of the relationship between maternal cART status and infant LTFU, we 
additionally excluded infants whose mothers enrolled in the UNC-DRC program before their 
most recent pregnancy.
Clinic visits for HIV-exposed infants were scheduled to occur every four weeks from the 
first visit at two weeks of age through 18 weeks of age and then every three months 
thereafter, with additional visits scheduled as clinically needed. Infants were considered 
confirmed HIV-negative and deactivated from care if they received a negative HIV virologic 
or serologic test result obtained more than three months after the cessation of breastfeeding. 
HIV-exposed infants diagnosed with HIV were eligible to receive ongoing HIV care and 
treatment in the UNC-DRC program. 9,10 For infants <18 months of age, HIV was 
diagnosed by virologic testing, with initial testing at six weeks of age and confirmatory 
virologic testing of all positive results performed on a second specimen. DNA PCR assays 
were implemented in Kinshasa in November 2009. Before that time, HIV RNA assays were 
the only available virologic HIV test and stock outs were frequent. Additional details on the 
program background and services provided to HIV-exposed infants are published 
elsewhere. 11
Definitions and Statistical analysis
Baseline was defined as infant enrollment and the outcome of interest was LTFU before 
confirmation of an HIV-positive or -negative status. Infants were considered LTFU on their 
last attended clinic visit date following three failed tracking attempts after a missed 
appointment or if more than six months passed since they were last seen in the clinic. The 
six-month cutoff was chosen based on empirical evidence from adult HIV treatment 
programs, which suggests that a cutoff of six months from the last attended clinic visit 
results in the least amount of outcome misclassification. 12 Infants who never returned for a 
follow-up visit were assigned a survival time of one day.
The primary exposure was baseline maternal cART status. The reference group included 
infants whose mothers initiated cART by the day of infant enrollment, which was provided 
according to World Health Organization (WHO) guidelines in effect at the time. Before 
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2010, all women with a CD4 cell count <200 cells/mm3 were eligible for cART 13. In 2010, 
the immunological cutoff increased to 350 cells/mm3 14.
Baseline characteristics of infants and their mothers were summarized using standard 
descriptive statistics. Infants were considered underweight if they had a weight-for-age Z-
score (WAZ) and stunted if they had a height-for-age Z-score (HAZ) more than two 
standard deviations below the median value for a given age group and sex. Z-scores were 
derived from the WHO Child Growth Standards 15 using the WHO Anthro software (version 
3.2.2, January 2011) and SAS macro. Growth status was based on the first available weight 
or height values measured within a month of enrollment. Maternal CD4 counts were based 
on the first available measurement within three months of infant enrollment.
All analyses were conducted in SAS 9.3 (SAS Institute, Inc., Cary, North Carolina). 
Accounting for competing risks, 16 the 18-month cumulative incidence of infant LTFU was 
estimated within strata of maternal cART status and baseline covariates. To quantify the 
association between maternal cART and infant LTFU, we used the SAS macro 
%PSHREG 17 to implement the proportional subdistribution hazards model of Fine and 
Gray 16,18. Crude and covariate-adjusted hazard ratios (HR), as well as corresponding 95% 
confidence limits (CL), were generated. In these analyses, follow-up began at infant 
enrollment and continued until the first of the following: the event of interest (LTFU), a 
competing event (death or graduation from care), or a censoring event (18 months of age or 
August 2013). Graduation from care was defined as being deactivated from care after 
confirmation of an HIV-negative status or transfer to ongoing HIV care and treatment 
following confirmation of an HIV-positive status. We also provide cause-specific HRs 
estimated from a Cox model for comparison.
Covariates included the baseline variables infant age, infant WAZ, maternal age, maternal 
CD4 count, maternal enrollment duration (defined as days since maternal enrollment in the 
UNC-DRC program), and time since the beginning of the study (defined as days between 
January 1, 2007 and the date of infant enrollment). The covariates were modeled with Stone 
and Koo's additive splines constrained to be linear in the tails, with knots at the 5th, 35th, 
65th, and 95th percentiles 19. To avoid excluding individuals with missing covariate data 
from the analysis, missing values were imputed using the sequential regression method 
described by Raghunathan et al. 20 and implemented in IVEware 0.2 (Institute for Social 
Research, University of Michigan, Ann Arbor, Michigan). Five complete datasets were 
generated and analyzed separately using standard statistical procedures. Results from the 
five complete datasets were combined using MIANALYZE procedures in SAS, which 
produce variance estimates that properly reflect the uncertainty due to missing values. To 
assess whether our results were sensitive to imputation assumptions, in a sensitivity analysis 
we compared results from the imputation analysis to results from a model that excluded the 
122 individuals with any missing covariate data (i.e. a complete-case analysis). While 
complete-case analysis is the most frequently implemented method for handling missing 
data and the default method in most commonly used statistical software programs, precision 
is reduced due to the diminished sample size and results from such analyses may be biased if 
the data are not missing completely at random. 21
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To inform the question of whether providing HIV-infected mothers with cART reduces 
LTFU of their HIV-exposed infants regardless of the health status of the mother, we 
secondarily assessed the HR for the effect of maternal cART on infant LTFU stratified by 
maternal CD4 cell count (<350 or 350+) at infant enrollment.
Ethics statement
All research was approved by the Ethics Committee of the Kinshasa School of Public Health 
and the University of North Carolina at Chapel Hill Institutional Review Board.
RESULTS
1736 HIV-exposed infants enrolled into care during the study period, of which 1318 were 
included in the analysis after exclusion criteria were applied (Figure 1). Infants included in 
the analysis enrolled at a median age of 2.6 weeks (interquartile range [IQR]: 2.1-6.9 
weeks), at which time 89% were breastfeeding, 21% were underweight, and 24% were 
stunted (Table 1). 1008 (76%) infants had mothers who had not yet initiated cART by infant 
enrollment (Figure 1).
Mothers were a median age of 31 years (IQR: 27-34 years) and had been enrolled in the 
UNC-DRC program for a median of 72 days (IQR: 0-126 days) at the time of infant 
enrollment (Table 1). The median enrollment duration was longer for mothers who initiated 
cART by infant enrollment than those who had not initiated cART (109 days versus 56 
days). Baseline maternal CD4 count also differed, with a higher proportion of mothers who 
initiated cART having a CD4 cell count <350 cells/mm3 than mothers who had not initiated 
cART (55% versus 30%). Mothers who initiated cART had been receiving cART for a 
median of 65 days (IQR: 32-102 days) by the time of infant enrollment.
Overall, 241 infants were LTFU over 13,365 person-months of follow-up and the unadjusted 
18-month cumulative incidence of LTFU was 18% (95% CL: 16, 21%). Many infants (5% 
[95% CL: 4, 7%]) never returned for a visit after enrolling in care, 9% (95% CL: 8, 11%) 
were LTFU within three months, and 13% (95% CL: 11, 15%) were LTFU within six 
months. An assessment of the 18-month cumulative incidence of LTFU within strata of 
baseline covariates suggested that older infant enrollment age, younger maternal age, and 
shorter maternal duration in care were associated with increased LTFU (Table 2). There did 
not appear to be differences in the 18-month cumulative incidences of LTFU between strata 
of other covariates, including maternal CD4 cell count.
Figure 2 shows the 18-month cumulative incidence function for infant LTFU within strata of 
maternal cART status at the mean value of baseline covariates; the 18-month estimate was 
8% (95% CL: 5, 11%) for infants whose mothers had initiated cART by baseline and 20% 
(95% CL: 17, 22%) for infants whose mothers had not yet initiated cART. In the unadjusted 
Fine and Gray subdistribution hazards model, the HR comparing LTFU among infants 
whose mothers did not receive cART by infant enrollment to those whose mothers did 
receive cART by infant enrollment was 2.42 (95% CL: 1.67, 3.64) (Table 3). Without 
imputing missing data, the covariate-adjusted HR was 3.13 (95% CL: 1.97, 4.98). After 
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multiple imputation was used to account for missing covariate data, the covariate-adjusted 
HR was 2.75 (95% CL: 1.81, 4.16). Using Cox regression, the unadjusted HR was 2.69 
(95% CL: 1.78, 4.05), the covariate-adjusted HR excluding infants with missing covariate 
data was 3.22 (95% CL: 2.00, 5.18), and the covariate-adjusted HR using multiple 
imputation for missing data was 2.82 (95% CL: 1.83, 4.35).
In stratified analyses, we observed a protective effect of providing HIV-infected mothers 
with cART on LTFU of their HIV-exposed infants among both maternal CD4 groups (<350 
and 350+) (Table 3). The association appeared stronger among infants whose mothers had a 
CD4 cell count ≥350 (subdistribution HR: 3.73 [95% CL: 1.76, 7.90]) at the time of infant 
enrollment compared to infants whose mothers had a CD4 cell count <350 (subdistribution 
HR: 2.14 [95%CI: 1.23, 3.70]).
DISCUSSION
In a large cohort of HIV-exposed infants in Kinshasa, DRC, we found that infants whose 
mothers had not yet initiated cART by infant enrollment were more than twice as likely to 
be LTFU than infants whose mothers had initiated cART. To our knowledge, this is the first 
study to report the cumulative incidence of infant LTFU within strata of maternal cART 
status and the first to quantify the association between maternal cART and LTFU of HIV-
exposed infants.
Two prior studies suggested that maternal cART is predictive of successful EID. The first 
study, which included 217 mother-infant pairs from Mozambique, found that mothers who 
received cART were more likely to ever bring their infant for a virological test compared to 
women who did not receive cART, with an odds ratio (OR) of 3.15 (95% CL: 1.02-9.73). 22 
A larger study that included 1,587 HIV-exposed infants in Cameroon examined the 
association between multiple predictors and having an incomplete EID process by seven 
months found that women who received no prophylaxis (OR: 2.3 [95% CL: 1.2-4.1]) or 
short-course prophylaxis (OR: 1.4 [95% CL: 0.9-2.1]) were more likely to have an 
incomplete EID process compared to women who received cART. 23
While those prior studies provide evidence for an association between maternal cART and 
EID, HIV-exposed infant care involves more than a single testing event due to continued 
exposure to HIV through breastfeeding 24. Regular follow-up of HIV-exposed infants is 
needed to administer additional HIV tests, communicate test results to caregivers, provide 
prophylactic drugs, and monitor breastfeeding. An important strength of our study is that we 
assessed LTFU through the entire HIV-exposed infant care cascade. Our findings suggest a 
strong beneficial effect of maternal cART on infant retention that persists beyond the initial 
HIV testing event. We observed that most infants who were LTFU were last seen at the 
clinic in the first six months of infant enrollment. Other studies have also described high 
rates of LTFU within the first few months. 2 To have the greatest impact on LTFU of HIV-
exposed infants, HIV-infected mothers should be started on cART as early as possible.
Other strengths of our study are the large sample size, relatively long follow-up time, and 
use of competing risk methods. Whether or not providing HIV-infected mothers with cART 
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predicts LTFU of their HIV-exposed infants is a function of both the effect of maternal 
cART on infant LTFU and the effect of maternal cART on the competing events (e.g. 
death). 16 We chose to use the subdistribution hazards model described by Fine and Gray in 
our primary analysis over a traditional Cox regression model because doing so allowed us to 
interpret the hazard ratio as a measure of risk without the added assumption that the event of 
interest (LTFU) was independent of the competing events (death and graduation from care). 
Since competing risks are common in routine care settings, we consider the subdistribution 
HR more informative for policy decisions about PMTCT strategies than the cause-specific 
HR from a Cox model. However, as the distribution of competing events may vary between 
populations, we chose to additionally report cause-specific HRs. In our study, the 
subdistribution and cause-specific HRs were similar.
The study sites provided routine care to a patient population that was likely representative of 
other patient populations in Kinshasa. HIV services were integrated into the existing 
healthcare system and supervised by the government. However, there are two points to note 
about the generalizability of our findings. First, mother-infant pairs in this study received 
PMTCT services at centralized clinics providing family-centered care. The effect of 
maternal cART on infant LTFU may not be as strong in settings where infants and their 
mothers do not receive co-located care. Although our results are also not directly 
generalizable to programs providing decentralized care, we suspect that a similar reduction 
in infant LTFU could be achieved by providing newly enrolled mothers cART in that setting 
and future studies should assess this. Second, we excluded 116 infants who could not be 
matched to a mother also receiving care in the UNC-DRC program. It is likely that most of 
the excluded infants were orphans; however we could not confirm this in our study because 
the orphan status of infants was not routinely documented by the UNC-DRC program. 
Routine documentation of orphan status is needed so that future studies can assess how to 
provide optimal PMTCT care for HIV-exposed infants who may have lost one or more 
caregiver.
Our central hypothesis was that the propensity of mothers on cART to seek care was higher 
than that for mothers not yet on cART, and that this corresponded with an increased 
likelihood of continuing to bring their infants for care. The propensity of mothers on cART 
to seek care may differ between populations, for example due to factors such as cART 
eligibility criteria and how sick mothers are when they initiate treatment. Whether maternal 
cART is associated with reduced infant LTFU in other implementation contexts should be 
assessed. In the UNC-DRC program, cART was provided to mothers in accordance with 
national guidelines in effect at the time, which meant that mothers were eligible for cART 
based on established immunological or clinical criteria. We attempted to account for this by 
adjusting for maternal CD4 count in the analysis. We also examined stratified effect 
estimates and saw a strong protective effect of maternal cART on infant LTFU in both the 
low and high maternal CD4 groups, which suggests that cART eligibility criteria were not 
driving the observed associations. Moreover, maternal CD4 count at infant enrollment was 
not predictive of infant LTFU in our study population.
The UNC-DRC program made up to three attempts to track infants who missed clinic 
appointments in order to encourage retention in care and correctly classify the mortality 
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status of infants who died. Although we used statistical methods that accounted for known 
deaths (3% among infants whose mothers were on cART and 5% among infants whose 
mothers were not on cART), it should be noted that the mortality status of infants who were 
LTFU is by definition unknown. Indeed, LTFU includes both individuals who are alive and 
lost from care, as well as individuals who died but were misclassified as LTFU.25 Thus it is 
not possible for us to tease out what portion of the effect of maternal cART on infant LTFU 
is attributable to differentials in mortality between the comparison groups versus other 
potential reasons for infant LTFU, such as those related to how cART affects the propensity 
of mothers to seek care for their children. These pathways should be assessed in future 
studies with dedicated resources for community-based tracing to determine the outcomes of 
HIV-exposed infants and their families.
Overall, our results suggest that providing cART to HIV-infected mothers may lead to 
improvements in the implementation of PMTCT care for HIV-exposed infants, including 
early infant diagnosis (EID) and timely cART initiation for those that are positive. This 
study specifically addressed the question of whether providing HIV-infected mothers with 
cART reduced LTFU of HIV-exposed infants after they presented to care. Another 
important loss point of HIV-exposed infants is the time between birth and uptake of follow-
up care. Whether or not maternal cART could also improve linkages to follow-up care for 
HIV-exposed infants remains unknown and should be established in future studies.
Little is known about other factors that contribute to LTFU among HIV-exposed infants. 
There is evidence to suggest that addressing structural barriers including cost, transportation, 
waiting time, and service quality may improve retention in the PMTCT setting. 22,26-30 
Addressing issues involving fatalistic attitudes around pediatric HIV and reducing fear of 
stigma and discrimination may also be important. 31. Covariates in this study that appeared 
to predict infant LTFU were older infant enrollment age, younger maternal age, and 
maternal enrollment duration.
Despite the fact that LTFU of HIV-exposed infants is an ongoing public health problem, it 
remains inadequately studied in part because quality individual-level data from HIV-
exposed infants are not widely available from field settings. The UNC-DRC program 
routinely collected prospective individual-level data on HIV-exposed infants and linked data 
between infants and their mothers. Such linkages are often difficult or impossible to obtain 
retrospectively, limiting the number of studies that are able to construct cohorts of mother-
infant pairs in order to assess the impact that maternal factors have on infant outcomes. 
Routine quality improvement activities implemented at the UNC-DRC sites, including 
active tracking of patients who missed clinic appointments, also assured that the data 
included in the analyses were of high quality.
In conclusion, providing HIV-infected mothers with cART could increase retention in care 
of their HIV-exposed infants. This is an important collateral benefit that countries should 
consider as they make decisions around the provision of cART for all pregnant and 
breastfeeding women (Options B/B+). 32 As LTFU remains an important barrier to 
delivering optimal care for HIV-exposed infants, explicit interventions to improve retention 
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of HIV-exposed infants should be prioritized, particularly in settings where cART is not 
provided to all mothers.
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Flowchart depicting the study population.
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18-month cumulative incidence function of loss to follow-up among HIV-exposed infants in 
Kinshasa, Democratic Republic of Congo, plotted by maternal combination antiretroviral 
therapy (cART) status at infant enrollment into care a.
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Table 1
Characteristics of HIV-exposed infants and their mothers at infant enrollment into care, by maternal 
combination antiretroviral therapy status, Kinshasa, Democratic Republic of Congo.
Maternal cART (N=310) No Maternal cART (N=1008) Overall (N=1318)
Median infant age in weeks (IQR) 2 (2, 3) 3 (2, 9) 3 (2, 7)
Calendar year at infant enrollment
        2007 15 (5) 112 (11) 127 (10)
        2008 30 (10) 158 (16) 188 (14)
        2009 65 (21) 279 (28) 344 (26)
        2010 68 (22) 224 (22) 292 (22)
        2011 132 (43) 235 (23) 367 (28)
Infant gender [N (%)]
        Female 156 (50) 513 (51) 669 (51)
        Male 154 (50) 495 (49) 649 (49)
Any PMTCT regimen [N (%)]
        Yes 307 (99) 786 (86) 1093 (89)
        No 3 (1) 127 (14) 130 (11)
Breastfeeding
        Yes 222 (91) 628 (89) 850 (89)
        No 23 (9) 78 (11) 101 (11)
Infant underweight
        Yes 57 (19) 210 (22) 267 (21)
        No 241 (81) 765 (78) 1006 (79)
Infant stunted
        Yes 66 (22) 236 (24) 302 (24)
        No 231 (78) 737 (76) 968 (76)
Median maternal age in years [IQR] 32 (29-35) 30 (26-34) 31 (27-34)
Median days mother enrolled [IQR] 109 (74-141) 56 (0-115) 72 (0-126)
Median days mother on cART 65 (32-102) N/A N/A
Maternal CD4 count
        <350 cells/mm3 163 (55) 278 (30) 441 (36)
        350+ cells/mm3 134 (45) 661 (70) 795 (64)
Abbreviations: cART, combination antiretroviral therapy; IQR, interquartile range; PMTCT, prevention of mother-to-child HIV transmission
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Table 2
18-month cumulative incidence of loss to follow-up within strata of baseline covariates, Kinshasa, Democratic 
Republic of Congo.
Cumulative incidence of LTFU 95% Confidence limit
Age at infant enrollment
        <4 weeks 17.1 (14.7, 19.8)
        4+ weeks 20.9 (17.0, 24.6)
Calendar year at infant enrollment
        2007-2008 18.8 (14.7, 23.4)
        2009-2011 18.4 (16.0, 20.9)
Underweight
        Yes 19.4 (14.8, 24.4)
        No 18.2 (15.8, 20.6)
Age of mother at infant enrollment
        <30 years 21.3 (18.1, 24.7)
        30+ years 16.2 (13.6, 19.0)
Enrollment duration of mother at infant enrollment
        <3 months 19.8 (17.1, 22.7)
        3+ months 16.6 (13.6, 20.0)
Maternal CD4 count at infant enrollment
        <350 cells/mm3 18.5 (14.7, 22.4)
        350+ cells/mm3 18.5 (15.7, 21.2)
Abbreviations: LTFU, loss to follow-up; PMTCT, prevention of mother-to-child transmission of HIV
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Table 3
Estimated effect of maternal combination antiretroviral therapy on loss to follow-up of HIV-exposed infants in 
Kinshasa, Democratic Republic of Congo.
LTFU (N) Person-months of follow-up Subdistribution hazard ratio 95% Confidence limit
Unadjusted Fine and Gray model
No maternal cART 212 9539 2.42 (1.67, 3.64)
Maternal cART 29 3827 1.
Covariate-adjusted Fine and Gray 
model, complete case
a
No maternal cART 178 8703 3.13 (1.97, 4.98)
Maternal cART 22 3575 1.
Covariate-adjusted Fine and Gray 
model, multiple imputation
b
No maternal cART 212 9426 2.75 (1.81, 4.16)
Maternal cART 29 3795 1.
Covariate-adjusted Fine and Gray 
model, multiple imputation, 
stratified by maternal CD4 at infant 
enrollment
c,d
CD4 <350, no maternal cART 65 2251 2.14 (1.23, 3.70)
CD4 <350, maternal cART 20 1927 1.
CD4 350+, no maternal cART 147 7288 3.73 (1.76, 7.90)
CD4 350+, maternal cART 9 1899 1.
Abbreviations: cART, combination antiretroviral therapy; LTFU, loss to follow-up
a
Fine and Gray subdistribution proportional hazards model adjusted for baseline variables, including infant age, infant WAZ, maternal age, 
maternal CD4 count, maternal enrollment duration, and calendar time. Infants with missing covariate data (N=122) were excluded from the 
analysis.
b
Fine and Gray subdistribution proportional hazards model adjusted for baseline variables, including infant age, infant WAZ, maternal age, 
maternal CD4 count, maternal enrollment duration, and calendar time. Missing data were imputed.
c
Fine and Gray subdistribution proportional hazards model adjusted for baseline variables, including infant age, infant WAZ, maternal age, 
maternal enrollment duration, and calendar time. Missing data were imputed.
d
Loss to follow-up counts and person-months of follow-up are the average from 5 imputed datasets.
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